Development and validation of new discriminative dissolution method for carvedilol tablets

Indian Journal of Pharmaceutical Sciences

Volumn 73, Issue 5, 2011, Pages 527-536

  Raju, V ^a   Murthy, K V R ^a  

^a ANDHRA UNIVERSITY   (India)

Author keywords

ANOVA based method; carvedilol; difference factor (f 1); discriminative dissolution; model dependent method; model independent method; similarity factor (f 2)

Indexed keywords

CADMOS; CARVEDILOL; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG;

ACCURACY; ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; FOOD AND DRUG ADMINISTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; QUALITY CONTROL; VALIDATION STUDY;

EID: 84864652560     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: 10.4103/0250-474X.99000     Document Type: Article

References (30)

1. Tzanavaras PD, Themelis DG, Zotou A, Stratis J, Karlberg B. Optimization and validation of a dissolution test for selegiline hydrochloride tablets by a novel rapid HPLC assay using a monolithic stationary phase. J Pharm Biomed Anal 2008;46:670-5.
2. Rossi RC, Dias CL, Donato EM, Martins LA, Bergold AM, Froehlich PE. Development and validation of dissolution test for ritonavir soft gelatin capsules based on in vivo data. Int J Pharm 2007;338:119-24. (Pubitemid 46777226)
3. Maggio RM, Castellano PM, Kaufman TS. A new principal component analysis-based approach for testing "similarity" of drug dissolution profiles. Eur J Pharm Sci 2008;34:66-77.
4. Hoti E, Censi R, Ricciutelli M, Malaj L, Barboni L, Martelli S, et al. Validation of an HPLC-MS method for rociverine tablet dissolution analysis. J Pharm Biomed Anal 2008;47:422-8.
5. Adams E, De Maesschalck R, De Spiegeleer B, Vander Heyden Y, Smeyers-Verbeke J, Massart DL. Evaluation of dissolution profiles using principal component analysis. Int J Pharm 2001;212:41-53. (Pubitemid 32121949)
6. Yuksel N, Kanik AE, Baykara T. Comparison of in vitro dissolution profiles by ANOVA-based, model-dependent and-independent methods. Int J Pharm 2000;209:57-67.
7. Brown CK, Chokshi HP, Nickerson B, Reed RA, Rohrs BR, Shah PA. Acceptable Analytical Practices for Dissolution Testing of Poorly Soluble Compounds. Pharm Technol 2004;28:56-65. (Pubitemid 39627754)
8. Carvalho-Silva B, Moreira-Campos LM, Nunan EA, Vianna-Soares CD, Araujo-Alves BL, Cesar IC, et al. Optimization and statistical evaluation of dissolution tests for indinavir sulfate capsules. Farmaco 2004;59:921-7. (Pubitemid 39488374)
9. He Z, Zhong D, Chen X, Liu X, Tang X, Zhao L. Development of a dissolution medium for nimodipine tablets based on bioavailability evaluation. Eur J Pharm Sci 2004;21:487-91. (Pubitemid 38283922)
10. Jamzad S, Fassihi R. Role of surfactant and pH on dissolution properties of fenofibrate and glipizide-a technical note. AAPS PharmSciTech 2006;7:E17-E22.
11. Eryol C, Demirturk E, Oner L. Preparation of meloxicam tablet formulations and evaluation of in vitro release similarities. FABAD J Pharm Sci 2004;29:53-61. (Pubitemid 40942297)
12. Pokharkar VB, Mandpe LP, Padamwar MN, Ambike AA, Mahadik KR, Paradkar A. Development, characterization and stabilization of amorphous form of a low Tg drug. Powder Technol 2006;167:20-5. (Pubitemid 44215984)
13. Wei L, Sun P, Nie S, Pan W. Preparation and evaluation of SEDDS and SMEDDS containing carvedilol. Drug Develop Ind Pharm 2005;31:785-94. (Pubitemid 41356195)
14. Agnihotri SA, Aminabhavi TM. Development of novel interpenetrating network gellan gum-poly(vinyl alcohol) hydrogel microspheres for the controlled release of carvedilol. Drug Develop Ind Pharm 2005;31:491-503. (Pubitemid 41285727)
15. Loftsson T, Vogensen SB, Desbos C, Jansook P. Carvedilol: solubilization and cyclodextrin complexation: A technical note. AAPS PharmSciTech 2008;9:425-30.
16. Rathod R, Prasad LP, Rani S, Nivsarkar M, Padh H. Estimation of carvedilol in human plasma by using HPLC-fluorescence detector and its application to pharmacokinetic study. J Chromatogr B: Anal Technol Biomed Life Sci 2007;857:219-23. (Pubitemid 47454566)
17. FDA Recommended Dissolution Methods, available from: Last accessed on 2010 Jan 11
18. Gannu R, Yamsani VV, Rao YM. New RP-HPLC method with UVdetection for the determination of carvedilol in human serum. J Liq Chromatogr Relat Technol 2007;30:1677-85. (Pubitemid 46641884)
19. O'Hara T, Dunne A, Butler J, Devane J. A review of methods used to compare dissolution profile data. Pharm Sci Technol Today 1998;1:214-23. (Pubitemid 28387122)
20. Patel N, Chotai N, Patel J, Soni T, Desai J, Patel R. Comparison of in vitro dissolution profiles of oxcarbazepine-HP-β-CD tablet formulations with marketed oxcarbazepine tablets. Dissol Technol 2008;15:28-34.
21. Polli JE, Rekhi GS, Shah VP. Methods to Compare Dissolution Profiles. Drug Inf J 1996;30:1113-20. (Pubitemid 26384608)
22. Polli JE, Rekhi GS, Augsburger LL, Shah VP. Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets. J Pharm Sci 1997;86:690-700. (Pubitemid 27248819)
23. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123-33. (Pubitemid 32288781)
24. Ahuja N, Katare OP, Singh B. Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. Eur J Pharm Biopharm 2007; 65:26-38. (Pubitemid 44827692)
25. FDA. Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms. Center for Drug Evaluation and Research (CDER), Food and Drug Administration, Rockville;1997.
26. Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol 1996;20:64-75.
27. Lee SL, Raw AS, Yu L. Dissolution testing. In: Krishna R, Yu L, editors, Biopharmaceutics Application in Drug Development, New Jersey: Springer; 2008. p 47-74.
28. Lagace M, Gravelle L, Di Maso M, McClintock S. Developing a discriminating dissolution procedure for a dual active pharmaceutical product with unique solubility characteristics. Dissol Technol 2004;11:13-8.
29. The United States Pharmacopoeia. The dissolution procedure: Development and validation. Pharmacopeial Forum 2004;30:351-63.
30. The United States Pharmacopoeia 29th ed. Rockville: The United States Pharmacopeial Convention; 2006.